Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.
Pacific Biosciences (PACB) Loss Wider Than Expected in Q1
by Zacks Equity Research
Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.
Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.
Cerner (CERN) Meets Q1 Earnings Estimates, Lowers '18 View
by Zacks Equity Research
Lower revenues stemming from lesser-than-expected subscription bookings hurt Cerner's (CERN) Q1 results.
Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.
CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow
by Zacks Equity Research
CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.
AmerisourceBergen (ABC) Q2 Earnings Top, FY18 View Solid
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and World Courier business in Q2.
NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.
Ecolab (ECL) Q1 Earnings & Revenues Top, '18 Guidance Solid
by Zacks Equity Research
Solid performance in Global Industrial and Global Institutional segments gave a boost to Ecolab's (ECL) earnings and revenues in Q1.
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View
by Zacks Equity Research
Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.
PerkinElmer (PKI) Q1 Earnings & Revenues Top, '18 View Up
by Zacks Equity Research
Solid prospects in PerkinElmer's (PKI) DAS segment are the key drivers of Q1. Strength in life sciences end markets, informatics profile and OneSource have given the top line a boost.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.
Hill-Rom (HRC) Earnings & Revenues Beat in Q2, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q2.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.
ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
GNC Holdings (GNC) Beats on Q1 Earnings, Plans Store Shutdown
by Zacks Equity Research
GNC Holdings (GNC) announces plans to shutter roughly 200 stores in 2018 as part of the ongoing optimization of the company's store portfolio in Q1.
Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.
Varian Medical (VAR) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Strong performance in the Software, Hardware and Service revenues boost Varian Medical's (VAR) Q2 results.
CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance
by Zacks Equity Research
CONMED (CNMD) gains on strong performance in core segments; raised guidance buoys optimism.
Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View
by Zacks Equity Research
Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.
Align Technology (ALGN) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Intuitive Surgical, Inc. (ISRG) Outperforming Other Medical Stocks This Year?